Work

Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Diabetes & Endocrinology

DOI: 10.1016/s2213-8587(24)00377-2

Authors: Takashi Kadowaki, Arihiro Kiyosue, Tomotaka Shingaki, Tomonori Oura, Koutaro Yokote

Institutions: Toranomon Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Eli Lilly (Japan), Chiba University

Language: English

Topic: Pharmacology and Obesity Treatment

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Eli Lilly and Company, Eli Lilly Japan

OpenAlex ID: W4408031363

FWCI: 28.06

Cites: 27

Cited by: 50

Related to: 10